재생의료 시장 보고서 : 유형, 용도, 최종사용자, 지역별(2026-2034년)

The global regenerative medicine market size reached USD 31.8 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 143.3 Billion by 2034, exhibiting a growth rate (CAGR) of 17.65% during 2026-2034. The increasing transplant rejection concerns, the rising demand for regenerative therapies for orthopedic conditions, the growing dental regeneration, and the escalating medicine use in wound healing are some of the factors propelling the market growth.

REGENERATIVE MEDICINE MARKET ANALYSIS:

• Major Market Drivers: The rising prevalence of chronic diseases such as diabetes, heart disease, and osteoarthritis owing to the aging population along with the growing research in stem cell therapies and genetic engineering drives innovation in regenerative medicine. Moreover, the escalating use of stem cells and other cell-based therapies for tissue regeneration and repair is also catalyzing the market.
• Key Market Trends: The increasing awareness among patients about regenerative treatment options along with the funding and regulatory support for regenerative medicine research and development is expected to boost the market demand. In addition to this, the advancements in biotechnology enable more precise and effective regenerative therapies, bolstering the market growth.
• Competitive Landscape: Some of the leading regenerative medicine market companies are bluebird bio, Inc., CRISPR Therapeutics, Gamida Cell Inc, Gilead Sciences, Inc., IOVANCE Biotherapeutics, Inc., Mesoblast Ltd, Novartis AG, Orchard Therapeutics plc, SanBio Co, Ltd., and Vertex Pharmaceuticals, among many others.
• Geographical Landscape: According to the report, North America accounted for the largest market share. Government agencies in the region have shown support for regenerative medicine research through funding initiatives, grants, and regulatory pathways designed to accelerate the development and commercialization of innovative therapies.
• Challenges and Opportunities: Regulatory hurdles in the approval of regenerative medicines along with the high cost of research, development, and clinical trials in regenerative medicines are hampering the market growth. However, advances in regenerative medicine, including cell therapy and gene editing technologies, enable personalized treatment approaches tailored to individual patient characteristics and disease profiles, further escalating the market demand.

REGENERATIVE MEDICINE MARKET TRENDS:

Increasing Product Demand in Cancer Treatment

The increasing product demand in cancer treatment is catalyzing the market growth. Cancer, characterized by uncontrolled cell growth, often leads to tissue damage, which can be addressed through regenerative therapies. Regenerative medicine allows for the development of targeted therapies that can repair damaged tissues caused by cancer or side effects of treatments like chemotherapy. For instance, according to an article published by Money Control in April 2024, stem cell therapy, also known as regenerative medicine, is a method of promoting the natural healing response of sick, malfunctioning, or wounded tissues by employing stem cells or their derivatives. Stem cell therapy uses stem cells to replace or repair damaged tissues, which has the potential to be an effective cancer treatment. Moreover, robust research and clinical trials explore the potential of regenerative therapies in various cancer types, fostering the market growth. The potential for regenerative therapies to revolutionize cancer treatment attracts investment in research and development. For instance, in April 2024, Denovo's DB107, a biomarker-guided late-stage gene therapy for high-grade glioma (HGG) including glioblastoma (GBM), received US$ 11.8 Million funding from the California Institute for Regenerative Medicine (CIRM) in order to perform a Phase 1/2 clinical trial of DB107 in patients with newly diagnosed HGG, a type of adult brain cancer. The rising prevalence of cancer and the pursuit of more effective, patient-friendly treatments fuel the demand for regenerative medicine in cancer care, contributing significantly to the market's expansion. These factors are further bolstering the regenerative medicine market revenue.

Rapid Advancements in Immunotherapy

Rapid advancements in immunotherapy are propelling the market. Immunotherapy, a subset of regenerative medicine, harnesses the body's immune system to fight diseases, including cancer and autoimmune disorders. Immunotherapies like CAR-T cell therapy and immune checkpoint inhibitors have revolutionized cancer treatment by enhancing the body's ability to recognize and combat cancer cells. For instance, according to an article published by Pen Medicine, CAR T cell therapy is a form of cancer immunotherapy treatment in which immune cells called T cells are genetically changed in a lab to help them locate and destroy cancer cells more efficiently. CAR T treatment can be extremely effective against certain forms of cancer, even when conventional treatments fail. They often have fewer severe side effects than traditional treatments like chemotherapy and radiation therapy, improving patient outcomes. Moreover, according to an article published by Web MD, immunotherapy has fewer side effects as it targets the immune system rather than the cells in the body. Moreover, robust clinical trials and research initiatives focus on optimizing immunotherapies, driving innovation in the field. For instance, in February 2024, Imunon announced the commencement of patient enrollment in IMNN-001, a Phase I/II clinical trial for DNA-based interleukin-12 (IL-12) immunotherapy in patients with advanced ovarian cancer at Memorial Sloan Kettering Cancer Center. The study intended to include fifty patients with Stage III/IV cancer. These factors are contributing to the regenerative medicine market share.

Widespread Product Applications in Cosmetic Surgery and Aesthetics

The widespread product applications in cosmetic surgery and aesthetics are a driving force behind the growth of this market. Regenerative therapies, including adipose-derived stem cell treatments, are used for natural tissue augmentation in procedures like breast reconstruction and facial rejuvenation. For instance, according to an article published by Umea University, adipose tissue stem cell transplantation makes it possible to regenerate a new breast without the need for silicone implants or extensive surgery following the removal of breast cancer. Moreover, regenerative techniques are employed to minimize the appearance of scars resulting from surgeries, accidents, or injuries, enhancing aesthetic outcomes. Stem cell-based regenerative therapies are utilized for hair restoration, addressing hair loss and baldness concerns. For instance, in March 2024, Aderans Company, the parent company of Bosley and HAIRCLUB, and Stemson Therapeutics signed an agreement to grant Stemson the sole right to conduct research, develop, and market hair regeneration therapeutic products based on Aderans' patented hair regeneration cell therapy technology. Through this collaboration, Stemson, a cell therapy developer in induced pluripotent stem cells (iPSC) for reversing hair loss, obtained a complementary technology. In addition to providing a variety of solutions for individuals suffering from hair loss, Stemson would take up Aderans' Phase 2 clinical-stage cell therapy hair regeneration program and incorporate the technology into its current hair loss cell therapy development pipeline. These factors are driving the adoption of regenerative medicine.

REGENERATIVE MEDICINE INDUSTRY SEGMENTATION:

Breakup by Type:

• Stem Cell Therapy
• Biomaterial
• Tissue Engineering
• Others

Stem cell therapy dominates the market

According to the regenerative medicine market outlook, stem cell therapy harnesses the unique regenerative properties of stem cells to repair and replace damaged or dysfunctional tissues and organs. It offers diverse therapeutic applications, including orthopedics, cardiology, neurology, and oncology. This versatility attracts investment and research, expanding its market presence. Clinical trials and case studies demonstrate the effectiveness of stem cell therapies in treating previously incurable conditions, boosting patient and physician confidence. With the global population aging, there's an increasing prevalence of age-related diseases and degenerative conditions, driving the demand for regenerative treatments. Furthermore, the regulatory bodies recognize stem cell therapies' potential, resulting in streamlined approvals and guidelines, further encouraging the market growth. Patients seeking alternatives to conventional treatments are turning to stem cell therapies for better outcomes and reduced side effects. The potential of stem cell therapies attracts investments, fostering research and development and expanding accessibility. Advances in stem cell isolation, culturing, and delivery methods improve treatment efficacy, enhancing their applications. Stem cell therapy providers are expanding their reach globally, making these treatments available to a wider patient population. For instance, in October 2022, Century Therapeutics and Bristol Myers Squibb revealed a research collaboration and license agreement to develop and market up to four induced pluripotent stem cell-derived, modified natural killer cell and/or T cell projects for hematologic malignancies and solid tumors.

Breakup by Application:

• Bone Graft Substitutes
• Osteoarticular Diseases
• Dermatology
• Cardiovascular
• Central Nervous System
• Others

Dermatology dominates the market

According to the regenerative medicine industry analysis, dermatology is a vital application within regenerative medicine, focusing on the restoration and regeneration of skin tissues. It addresses a wide spectrum of dermatological concerns, ranging from scar reduction and wound healing to treating skin disorders and aging-related skin conditions. Regenerative approaches in dermatology include using stem cells, growth factors, and tissue engineering techniques, offering patients innovative and minimally invasive solutions for achieving healthier, more youthful, and blemish-free skin. This segment is gaining traction due to the growing demand for cosmetic and aesthetic enhancements and the need for effective treatments for various skin ailments, ultimately contributing to the overall growth of the regenerative medicine market. For instance, in September 2023, Dr. Samuel Lynch, a biotechnology entrepreneur, launched Lynch Regenerative Medicine, Inc. (LRM), a new advanced biotherapeutics skincare firm that would address unmet clinical requirements in both the cosmetic and advanced wound care industry.

Breakup by End User:

• Hospitals
• Specialty Clinics
• Others

Hospitals dominate the market

As per the regenerative medicine industry insights, hospitals serve as prominent end users within the regenerative medicine market, playing a pivotal role in the adoption and growth of regenerative therapies. They serve as hubs for advanced medical care and are integral for several reasons. Hospitals provide the infrastructure and expertise necessary for conducting complex regenerative procedures, such as organ transplants and stem cell therapies, ensuring patient safety and optimal outcomes. They also facilitate clinical trials and research initiatives, allowing for the development and testing of innovative regenerative treatments. Furthermore, hospitals are key in delivering regenerative therapies to patients, especially for acute injuries, chronic diseases, or conditions requiring specialized medical attention. As healthcare institutions embrace regenerative medicine, hospitals remain central in its expansion, offering cutting-edge treatments to a diverse patient population.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America exhibits a clear dominance, accounting for the largest market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

As per the regenerative medicine industry statistics, North America represents a significant region in the regenerative medicine market, driving growth through several key factors. The region's advanced healthcare infrastructure, robust research and development capabilities, and high healthcare expenditure contribute to the adoption of regenerative therapies. It is home to numerous renowned research institutions, biotechnology companies, and academic centers specializing in regenerative medicine, fostering innovation and clinical advancements. Regulatory support and well-defined approval processes in countries like the United States accelerate the introduction of regenerative treatments to the market. A growing aging population with age-related conditions also fuels the demand for regenerative solutions. Moreover, a strong focus on addressing chronic diseases, sports injuries, and aesthetic concerns further propels the use of regenerative therapies in North America. These factors collectively position North America as a prominent growth driver in the regenerative medicine sector. For instance, in October 2023, Bayer AG inaugurated its first Cell Therapy launch facility in Berkeley, California, in order to offer regenerative medicines to patients.

COMPETITIVE LANDSCAPE:

Top companies are strengthening the market through innovation, strategic partnerships, and extensive research. They invest heavily in research and development, pushing the boundaries of regenerative medicine, uncovering new therapies, and expanding treatment options. They conduct large-scale clinical trials to demonstrate the safety and efficacy of regenerative therapies, gaining regulatory approvals and boosting market confidence. Top companies develop a diverse portfolio of regenerative products, catering to various medical conditions and applications, from orthopedics to oncology. These companies expand globally, ensuring wider access to their therapies and increasing market reach. Partnerships with research institutions, healthcare providers, and pharmaceutical companies facilitate knowledge sharing and the development of novel therapies. They navigate complex regulatory landscapes, ensuring their therapies meet stringent safety and quality standards instilling trust in healthcare professionals and patients. Top companies engage in patient advocacy and education, raising awareness about the benefits of regenerative medicine, thus driving demand. Their track record of success attracts investments, enabling further research and development of groundbreaking therapies.

The report has provided a comprehensive analysis of the competitive landscape in the regenerative medicine market. Detailed profiles of all major companies have also been provided.

• bluebird bio, Inc.
• CRISPR Therapeutics
• Gamida Cell Inc
• Gilead Sciences, Inc.
• IOVANCE Biotherapeutics, Inc.
• Mesoblast Ltd
• Novartis AG
• Orchard Therapeutics plc
• SanBio Co, Ltd.
• Vertex Pharmaceuticals

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Regenerative Medicine Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Stem Cell Therapy
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Biomaterial
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Tissue Engineering
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Others
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Application

• 7.1 Bone Graft Substitutes
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Osteoarticular Diseases
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Dermatology
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Cardiovascular
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Central Nervous System
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Others
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Specialty Clinics
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 bluebird bio, Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 CRISPR Therapeutics
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Gamida Cell Inc
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Gilead Sciences, Inc.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 IOVANCE Biotherapeutics, Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Mesoblast Ltd
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Novartis AG
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Orchard Therapeutics plc
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 SanBio Co, Ltd.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Vertex Pharmaceuticals
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis